ABSTRACT
The gold standard for the assessment of the vitreoretinal interface (VRI) is high resolution OCT. It is therefore essential to select the appropriate scan modalities to detect all morphological changes in different diseases, not only at the VRI, but also in all layers of the retina and in the foveal and parafoveal areas. These can be raster scans, radial scans or "en face" scans. Morphological changes at the VRI and especially in the outer retinal layers are good prognostic factors in high resolution OCT for the success of surgery for vitreomacular interface disorders. The following article gives an overview of current OCT procedures as well as correlations between morphological and functional findings.
Subject(s)
Retinal Diseases/diagnostic imaging , Retinal Diseases/pathology , Retinoscopes , Tomography, Optical Coherence/instrumentation , Child , Child, Preschool , Equipment Design , Equipment Failure Analysis , Female , Germany , Humans , Image Enhancement/instrumentation , Image Enhancement/methods , Infant , Infant, Newborn , Male , Miniaturization , Pediatrics/instrumentation , Reproducibility of Results , Retinoscopy/methods , Sensitivity and Specificity , Tomography, Optical Coherence/methodsABSTRACT
The detachment of the neurosensory retina from the underlying retinal pigment epithelium can be related to breaks of the retina allowing vitreous fluid to gain access to the subretinal space, to exudative changes of the choroid such as tumours or inflammatory diseases or to excessive tractional forces exerted by interactions of the collagenous vitreous and the retina. Tractional retinal detachment is usually treated by vitrectomy and exudative detachment can be addressed by treatment of the underlying condition in many cases. In rhegmatogenous retinal detachment two different surgical procedures, vitrectomy and scleral buckling, can be applied for functional and anatomic rehabilitation of our patients. The choice of the surgical procedure is not really standardised and often depends on the experience of the surgeon and other more ocular factors including lens status, the number of retinal breaks, the extent of the detachment and the amount of preexisting PVR. Using both techniques, anatomic success rates of over 90â% can be achieved. Especially in young phakic patients scleral buckling offers the true advantage to prevent the progression of cataract formation requiring cataract extraction and intraocular lens implantation. Therefore, scleral buckling should be considered in selected cases as an alternative surgical option in spite of the very important technical refinements in modern vitrectomy techniques.
Subject(s)
Ophthalmologic Surgical Procedures/methods , Retinal Detachment/surgery , Humans , Postoperative Complications/classification , Postoperative Complications/diagnosis , Postoperative Complications/etiology , Postoperative Complications/surgery , Prognosis , Recurrence , Reoperation , Retinal Detachment/classification , Retinal Detachment/diagnosis , Retinal Detachment/etiology , Risk Factors , Scleral Buckling/methods , Treatment Outcome , Vitrectomy/methods , Vitreous Detachment/classification , Vitreous Detachment/diagnosis , Vitreous Detachment/etiology , Vitreous Detachment/surgeryABSTRACT
PURPOSE: The present study investigated the treatment effect of dexamethasone implant (Ozurdex®, group 1) and anti-VEGF injection (Lucentis®, group 2) in course of macular oedema due to retinal vein occlusion in a retrospective, non-randomised case series. MATERIAL AND METHODS: Group 1 comprised 60 patients (31 with CRVO and 29 with BRVO) and group 2 included 52 patients, 27 with CRVO and 25 with BRVO) and both groups were further treated in case of recurrence. Preoperative and in monthly intervals best corrected visual acuity (BCVA), central retinal thickness using SD-OCT (Spectralis, Heidelberg Engineering), intraocular pressure, biomicroscopy status and a fundus photo documentation (Optomap) were evaluated. The primary clinical endpoint was visual acuity 12 months after the first intravitreal therapy, while secondary endpoints included the central retinal thickness change and safety of therapy. RESULTS: In group 1, an increase of BCVA (± standard deviation) of 8.4 (± 1.9) letters was observed in CRVO patients and a gain of 10.7 (± 3.8) letters in BRVO patients after 12 months, while in group 2, an increase of BCVA of 6.9 (± 1.9) letters (CRVO) compared to 12.5 (± 3.7) letters (BRVO) was observed after the same time span. In both groups a significant reduction in retinal thickness was achieved. An increase of intraocular pressure above 5 mmHg was observed in nearly half of the cases In group 1, but was well controlled by conservative antiglaucomatous therapy. We observed a progression of lens opacity in approximately 50â% of the cases in group 1. CONCLUSION: The treatment with Ozurdex compared to Lucentis appears to provide a trend towards a better although not significant visual acuity increase after 12 months in CRVO patients. A similar trend favouring anti-VEGF treatment with Lucentis was seen in patients with BRVO. However, the lens status and age of the patient should be taken into account when considering a treatment with Ozurdex.
Subject(s)
Drug Implants/administration & dosage , Macular Edema/drug therapy , Macular Edema/etiology , Retinal Vein Occlusion/complications , Retinal Vein Occlusion/drug therapy , Female , Humans , Intraocular Pressure/drug effects , Intravitreal Injections , Macular Edema/diagnosis , Male , Middle Aged , Recovery of Function/drug effects , Retinal Vein Occlusion/diagnosis , Retrospective Studies , Treatment Outcome , Visual Acuity/drug effectsABSTRACT
BACKGROUND: The aim of this investigation was to evaluate the effect on the anatomic surgical success with the changeover from 20 Gauge (G) (n = 206) to 23 G (n = 107) pars plana vitrectomy (PPV) in rhegmatogenous retinal detachment. METHODS: 313 consecutive patients were retrolective-prospectively analysed. Several parameters including lens status, number of retinal breaks, extent of retinal detachment, proliferative vitreoretinopathy (PVR) and refractive error were examined. Primary success rate was defined as anatomic success after a minimum follow-up of 6 months. The secondary success rate was determined as anatomic success after one further operation if necessary. Moreover recurring retinal detachment after initial success was registered. In additional to the analysis over all patients, cases were grouped according to the severity of the preoperative baseline situation. RESULTS: Primary success rate was 87.4â% for 20 G PPV and 87.9â% for 23 G PPV, secondary success rate was 95.6â% for 20 G PPV and 94.4â% for 23 G PPV. 13.9â% (20 G) and 7.4â% (23 G) of patients with initially reattached retina after one surgery developed recurrent retinal detachment in the follow-up and were successfully treated in 17/25 and 7/7 cases. With 20 G PPV a primary success rate of 85â% was obtained in phakic eyes and 89.6â% in pseudophakic eyes, respectively. However, primary success rate with 23 G PPV was 90.4â% for phakic eyes and 85.5â% for pseudophakic eyes. For simple, medium and severe cases, the primary success rate decreased from 97.1 to 92.4 and 74.2â% in 20 G PPV, whereas no obvious tendency appeared for 23 G PPV (93.9, 83.7, 88â%). In 20 G PPV surgery the lens status had no influence on the primary success rate (p > 0.05), for medium and severe cases in 23 G PPV better results were obtained in phakic eyes (88.5 and 93.3â%) compared to pseudophakic eyes (78.3 and 80â%, n.âs.). CONCLUSION: 20 G PPV as well as 23 G PPV are good surgical techniques in rhegmatogenous retinal detachment. Overall the miniaturisation of surgical instruments seems to be without any disadvantage for the surgical success.
Subject(s)
Minimally Invasive Surgical Procedures/instrumentation , Minimally Invasive Surgical Procedures/methods , Retinal Detachment/pathology , Retinal Detachment/surgery , Vitrectomy/instrumentation , Vitrectomy/methods , Aged , Equipment Design , Equipment Failure Analysis , Female , Humans , Male , Middle Aged , Miniaturization , Retrospective Studies , Treatment OutcomeABSTRACT
BACKGROUND: The purpose of this study is to establish the correlation between functional and morphological aspects before and 12 months after macular hole surgery. METHODS: In this prospective, interventional, consecutive study 16 eyes of 16 patients were included. All eyes received a successful transconjunctival 23-gauge vitrectomy with ILM peeling after initial diagnosis and maximum duration of symptoms of two months. Preoperatively and 3, 6 and 12 months postoperatively determinations of best-corrected visual acuity (logMAR), a 10° microperimetry (MP-1) and a spectral-domain based optical coherence tomography (SD-OCT) examination were performed. The photoreceptor layer (inner and outer segment, IS/OS) was evaluated based on SD-OCT images and correlated with data assessed by microperimetry analysis in the foveal and parafoveal region. RESULTS: After three months a stabilisation of BCVA with regeneration of the IS/OS line, an improvement of the fixation behaviour and the macular sensitivity could be observed. A significant restitution of the IS/OS line was observed after 12 months. Best corrected visual acuity, mean overall macular sensitivity and fixation improved significantly within the twelve month observation period (p < 0.05). Comparison of patients with at least two lines of visual acuity gain with patients having less than two lines of visual acuity gain 12 months after surgery showed no statistically significant difference in regeneration of the IS/OS integrity in the fovea (p = 0.433), but a difference was seen in the parafoveal region. A postoperative visual acuity gain of at least two lines was significantly more often seen in eyes with postoperative continuous IS/OS line in the parafoveal sectors compared to eyes with persistent IS/OS defects (p < 0.02). CONCLUSION: Correlations of morphological and functional improvements can be observed after successful micro-invasive macular hole surgery. The extent of the preoperative IS/OS defect, particularly in the parafoveal region, is a good predictive parameter for the postoperatively obtained macular sensitivity. The prediction of the postoperative visual acuity should not be made on the basis of a single clinical, anatomic finding.
Subject(s)
Macula Lutea/pathology , Macula Lutea/surgery , Recovery of Function , Retinal Perforations/diagnosis , Retinal Perforations/surgery , Vision Disorders/diagnosis , Vision Disorders/prevention & control , Vitrectomy , Aged , Female , Humans , Male , Middle Aged , Retinal Perforations/complications , Statistics as Topic , Treatment Outcome , Vision Disorders/etiology , Visual AcuityABSTRACT
BACKGROUND: It is currently still not clarified whether diving using a self-contained breathing apparatus (SCUBA) is associated with intraocular pressure (IOP) fluctuations of clinical relevance and whether intensive diving could exacerbate the damage in glaucoma patients. OBJECTIVE: This study aimed to evaluate the effect of SCUBA diving on IOP in healthy volunteers without prior eye injuries or surgery. HYPOTHESIS: recreational diving does not lead to significant increases or fluctuations of the IOP. MATERIAL AND METHODS: The study included 16 divers (5 female) who performed a total of 96 dives with air or nitrox32 to a depth of 20-30â¯m for an average of 50â¯min. The central cornea thickness was measured using ultrasonic pachymetry Pocket IITM (Quantel Medical Pocket II™, Quantel Medical, Clermont-Ferrand, France), and the IOP was measured using an Icare® PRO (Icare® PRO, Icare Finland Oy, Espoo, Finland) directly before the dive and 10â¯min after surfacing. RESULTS: All data refer to the right eye. Average IOP values ranged from 15.6 to 19.2â¯mmâ¯Hg pre-dive and 16.8 to 18.2â¯mmâ¯Hg post-dive. The range of IOP values was 2.2-11.5â¯mmâ¯Hg pre-dive (∆â¯= 9.3â¯mmâ¯Hg) and 2.7-14.8â¯mmâ¯Hg post-dive (∆â¯= 12.1â¯mmâ¯Hg). Of the divers 11.5% vs. 18.8% had increased IOP values >â¯21â¯mmâ¯Hg (pre-dive vs. post-dive). CONCLUSION: This study found no significant differences in IOP values between pre-dive and post-dive measurements in healthy SCUBA divers. Therefore, recreational SCUBA diving is unlikely to affect the IOP in healthy individuals.
Subject(s)
Diving , Glaucoma , Humans , Female , Diving/adverse effects , Intraocular Pressure , Eye , ManometryABSTRACT
BACKGROUND: To evaluate the different treatment strategies for eyes with vitreomacular traction (VMT) and macular holes (MF) regarding the indications and initiation of treatment. OBJECTIVE: The aim of this study is to facilitate clinical decision making by presenting the opinions of experienced retinal specialists in the context of the current literature and the changed approval situation for ocriplasmin. MATERIAL AND METHODS: Members of the German Retina Society (RG) were questioned in an online survey. Based on a literature review a 100-question questionnaire was created and sent to all members of the RG via an electronic link to the online platform "LimeSurvey". Voluntary participation was possible from 15 October 2021 to 15 November 2021. Data collection and statistical analysis were anonymized. RESULTS: The responses of the 115 participants were congruent with the presentation of the new S1 guidelines on this topic. The indications for active treatment of focal VMT without MF were postponed in favor of watchful waiting, with the individual symptoms of the patient playing a major role in the proposed temporal management. The results on the indications for vitrectomy are consistent and convincingly confirm the opinions on the efficacy and risk assessment of this therapeutic procedure. CONCLUSION: The results presented provide an overview of the consensus and controversies in the current treatment options for VMT and MF. With the help of a homogeneous and experienced group of retinal experts, it was possible to develop individual treatment strategies.
ABSTRACT
It still remains unclear to which extent the presence and the amount of retinal debris seen in internal limiting membrane (ILM) specimens harvested during macular surgery for macular holes or epiretinal membranes are related to the procedure of ILM peeling itself or to modifications of the surgical technique, such as application of vital dyes for visualization of the ILM, or to pathological conditions with epiretinal membrane formation at the vitreoretinal interface. The presence of cellular fragments on the retinal side of the removed ILM appears to be of multifactorial origin, and additional causes besides dye application need to be considered. However, morphological studies with evaluation of vital dyes are still of relevance and provide additional insights into the ultrastructure of the vitreoretinal interface and its interaction with adjuvants used during macular surgery. Chromovitrectomy is an emerging field in vitreoretinal surgery. It is of importance to better understand the tissue-dye interactions, which not only alter the mechanical properties of the tissue being stained, but may also have an impact on the functional result postoperatively.
Subject(s)
Basement Membrane/ultrastructure , Coloring Agents , Retina/ultrastructure , Vitrectomy/methods , Vitreous Body/ultrastructure , Basement Membrane/surgery , Benzenesulfonates/adverse effects , Coloring Agents/adverse effects , Humans , Indocyanine Green/adverse effects , Microscopy, Atomic Force , Microscopy, Electron, Transmission , Retina/drug effects , Staining and Labeling/methods , Vitreous Body/drug effectsABSTRACT
BACKGROUND: Multikinase inhibitors (MKI) interfere effectively at different levels of the neovascularisation cascade. Early clinical and experimental data suggest that MKIs represent a promising novel approach for the treatment of neovascular age-related macular degeneration (AMD). However, so far little is known about the biocompatibility of MKIs regarding human ocular cells. This in vitro study investigates and compares the biocompatibility of three MKIs, axitinib, pazopanib, and sorafenib regarding ocular cells of the anterior and posterior segments, as well as organ-cultured donor corneas. METHODS: Primary human optic nerve head astrocytes (ONHA), trabecular meshwork cells (TMC), and retinal pigment epithelium (RPE), human corneal endothelial and lens epithelial cells (CEC and LEC) were treated with different concentrations of axitinib, pazopanib, or sorafenib (0.1 to 100 µg/mL). To simulate oxidative stress, the cells were additionally co-incubated with 400 µM hydrogen peroxide. Induction of cell death and cellular viability were examined by live-dead assay and tetrazolium dye reduction assay (MTT). In addition, the influence of the three substances on human corneal endothelium was evaluated in seropositive donor corneas in organ culture by phase contrast microscopy. RESULTS: Up to a concentration of 7.5 mg/mL of the substances tested in any cell type examined, no toxic effects were found. Even after 10 days of incubation of organ-cultured donor corneas with 7.5 µg/mL, axitinib, pazopanib, or sorafenib, no evidence for endothelial toxicity was found. CONCLUSION: All three MKIs tested, axitinib, pazopanib, and sorafenib showed a good biocompatibility on the investigated ocular cells. Even under conditions of oxidative stress, there were no toxic effects up to a concentration of 7.5 µg/mL. Only at higher concentrations, there was a dose-dependent decrease in cellular viability and pronounced induction of cell death. These effects on cellular viability and induction of cell death appeared to be stronger with pazopanib, followed by sorafenib, than with axitinib.
Subject(s)
Angiogenesis Inhibitors/pharmacology , Cell Survival/drug effects , Imidazoles/pharmacology , Indazoles/pharmacology , Niacinamide/analogs & derivatives , Phenylurea Compounds/pharmacology , Protein Kinase Inhibitors/pharmacology , Pyrimidines/pharmacology , Sulfonamides/pharmacology , Wet Macular Degeneration/drug therapy , Wet Macular Degeneration/pathology , Angiogenesis Inhibitors/adverse effects , Astrocytes/drug effects , Astrocytes/pathology , Axitinib , Cornea/drug effects , Cornea/pathology , Dose-Response Relationship, Drug , Endothelial Cells/drug effects , Endothelial Cells/pathology , Endothelium, Corneal/drug effects , Endothelium, Corneal/pathology , Humans , Imidazoles/adverse effects , Indazoles/adverse effects , Lens, Crystalline/drug effects , Lens, Crystalline/pathology , Microscopy, Phase-Contrast , Niacinamide/adverse effects , Niacinamide/pharmacology , Optic Disk/drug effects , Optic Disk/pathology , Organ Culture Techniques , Oxidative Stress/drug effects , Phenylurea Compounds/adverse effects , Protein Kinase Inhibitors/adverse effects , Pyrimidines/adverse effects , Retinal Pigment Epithelium/drug effects , Retinal Pigment Epithelium/pathology , Sorafenib , Sulfonamides/adverse effects , Trabecular Meshwork/drug effects , Trabecular Meshwork/pathologyABSTRACT
BACKGROUND: The aim of this study was to evaluate the fixation and other functional and morphological alterations in patients with diabetic macular oedema (DMO) under intravitreal ranibizumab therapy. PATIENTS AND METHODS: Thirty patients (39 eyes) with DMO with central involvement were included in this prospective study. Morphological (fluorescein angiography, OCT) as well as functional (visual acuity, microperimetry including fixation) parameters were analysed before and after three monthly intravitreal applications of ranibizumab. RESULTS: Best-corrected mean visual acuity (BCVA) increased significantly by 6.85 + 6.45 letters from 26.15 ± 13.83 to 33.03 ± 13.31 letters. Mean central retinal thickness and mean central retinal volume decreased significantly from 503.72 ± 143.78 µm, respectively (p < 0.001) before treatment to 387.05 ± 122.02 µm after the third intravitreal injection with ranibizumab. Mean retinal sensitivity obtained with microperimetry did not change significantly over the course of treatment. Mean fixation within 2° (4°) improved from 64.15 % (85.7 %) before treatment significantly to 70.15 % (91.5 %) after three intravitreal injections with ranibizumab. Mean fixation stability within 2° improved from 43.9 % before treatment significantly to 58.5 % after three intravitreal injections. CONCLUSION: DMO improved both morphologically with a significant reduction of central retinal thickness and volume and a significantly improved BCVA as well as fixation and fixation stability over the course of three monthly intravitreal injections with ranibizumab. Retinal sensitivity obtained in microperimetry did not change significantly over the course. Based on our observations we interpret and suggest fixation and fixation stability as an early functional parameter and prior to microperimetrically detectable changes of retinal sensitivity additional to BCVA during treatment of diabetic macular edema.
Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Diabetic Retinopathy/diagnosis , Diabetic Retinopathy/drug therapy , Fixation, Ocular/drug effects , Macular Edema/diagnosis , Macular Edema/drug therapy , Vision Disorders/prevention & control , Angiogenesis Inhibitors/administration & dosage , Diabetic Retinopathy/complications , Female , Humans , Intravitreal Injections , Macular Edema/complications , Male , Middle Aged , Ranibizumab , Treatment Outcome , Vision Disorders/diagnosis , Vision Disorders/etiology , Visual Acuity/drug effectsABSTRACT
OBJECTIVE: The aim of this study was to evaluate the functional outcome of Brilliant Blue G (BBG) and the staining properties in macular surgery. METHODS: BBG was applied during vitrectomy for macular holes (n = 21) or epiretinal membranes (n = 18) in a prospective, non-comparative consecutive series of patients (Brilliant Peel®; Fluoron® GmbH, Neu-Ulm, Germany). Before and after surgery all patients underwent a complete clinical examination including measurement of best corrected visual acuity and intraocular pressure, perimetry, fundus photography and optical coherence tomography. RESULTS: Vitrectomy was performed in combination with a cataract operation in 14 patients. All macular holes were closed successfully. Visual acuity was in average 0.16 preoperatively in macular hole cases and increased up to 0.4 after 6 months. Visual acuity of patients with epiretinal membranes changed on average from 0.3 to 0.45 after 6 months. The retina thickness in patients with epiretinal membranes was initially 402.6 µm according to the OCT and 304.7 µm after 6 months postoperatively. No toxic effects attributable to the dye were noted during patient follow-up, especially all perimetry tests were normal. CONCLUSIONS: Brilliant blue provides a sufficient and selective staining of the ILM. No retinal toxicity or adverse effects related to the dye were observed in this study. The long-term safety of this dye will have to be evaluated in larger patient series and a longer follow-up.
Subject(s)
Epiretinal Membrane/surgery , Indicators and Reagents , Retinal Perforations/surgery , Rosaniline Dyes/administration & dosage , Vitrectomy , Aged , Aged, 80 and over , Cataract Extraction , Combined Modality Therapy , Female , Fluorescein Angiography , Follow-Up Studies , Humans , Lenses, Intraocular , Male , Middle Aged , Postoperative Complications/diagnosis , Prospective Studies , Rosaniline Dyes/toxicity , Tomography, Optical Coherence , Visual Acuity , Visual Field TestsABSTRACT
Using high-resolution imaging, such as optical coherence tomography (OCT), the different layers of the retina as well as the vitreoretinal interface and its alterations can be very clearly differentiated. This includes the morphological characteristics of tractive maculopathies, such as epiretinal gliosis and vitreomacular traction syndrome. Additionally, structural alterations of the various layers of the neurosensory retina as a result of traction due to these pathologies can be demarcated. The latter have been investigated in clinical trials and evaluated as OCT biomarkers with respect to their prognostic and predictive value. In this review we would like to present and discuss various OCT biomarkers in the context of epimacular membranes and vitreomacular traction syndrome.
Subject(s)
Retinal Diseases , Tomography, Optical Coherence , Biomarkers , Humans , Retina , Retinal Diseases/diagnostic imaging , TractionABSTRACT
BACKGROUND: Biomarkers are characteristic biological measurable signs and objective parameters to detect the state of health. Besides functional and temporal factors, imaging biomarkers play an increasingly important role. In full-thickness and lamellar defects of the macula numerous imaging parameters have been described. This knowledge resulted in new classifications for both clinical pictures, which are based on important biomarkers of these clinical pictures and characteristic features of described subtypes. METHODS: Imaging biomarkers for full-thickness and lamellar macular defects are described with respect to the classification and their functional prognostic importance. The importance of these biomarkers is presented. RESULTS: The current classification of full-thickness and lamellar macular defects is based on structural biomarkers. Biomarkers are important for prognostic and therapeutic evaluation and they have an impact on the surgical strategy. There are various surgical strategies for treatment of full-thickness macular holes depending on the size of the foramen and other biomarkers. The inverted ILM flap technique improves the closure rate of large macular holes. In lamellar macular holes showing signs of progression an early surgical intervention results in a good anatomical and functional prognosis. CONCLUSION: Multimodal diagnostics provide important preoperative, intraoperative, and postoperative features for macular holes and lamellar macular holes, which are essential biomarkers for the exact classification, the therapeutic strategy and for assessment of the prognosis.
Subject(s)
Epiretinal Membrane , Retinal Perforations , Biomarkers , Epiretinal Membrane/surgery , Humans , Retinal Perforations/surgery , Retrospective Studies , Tomography, Optical Coherence , VitrectomyABSTRACT
OBJECTIVES: Growth factors, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and placenta growth factor (PlGF) are key players in the development of diabetic retinopathy, age-related macular degeneration, and other retinal neovascular diseases. Glial cells provide a significant source of retinal growth factor production under physiologic and pathologic conditions. Cumulative light exposure has been linked to increased retinal growth factor expression. Previous reports indicate that sorafenib, an oral multikinase inhibitor, might have a beneficial effect on retinal neovascularization. This study was designed to investigate the effects of sorafenib on light-induced overexpression of growth factors in human retinal glial cells. METHODS: Primary human optic nerve head astrocytes (ONHAs) were exposed to white light and incubated with sorafenib. Viability, expression, and secretion of VEGF-A, PDGF-BB, and PlGF and their mRNA were determined by reverse transcription-polymerase chain reaction, immunohistochemistry, and enzyme-linked immunosorbent assay. RESULTS: Light exposure decreased cell viability and increased VEGF-A, PDGF-BB, and PlGF expression and secretion. These light-induced effects were significantly reduced when cells were treated with sorafenib at a concentration of 1 microg/ml. CONCLUSION: Sorafenib significantly reduced light-induced overexpression of VEGF-A, PDGF-BB, and PlGF in primary human ONHAs. Sorafenib has promising properties as a potential supportive treatment for retinal neovascularization.
Subject(s)
Benzenesulfonates/pharmacology , Optic Disk/drug effects , Platelet-Derived Growth Factor/antagonists & inhibitors , Pregnancy Proteins/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Pyridines/pharmacology , Retina/drug effects , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Adult , Aged , Astrocytes/drug effects , Astrocytes/radiation effects , Benzenesulfonates/therapeutic use , Cell Survival/drug effects , Cell Survival/radiation effects , Humans , Light/adverse effects , Middle Aged , Niacinamide/analogs & derivatives , Optic Disk/immunology , Optic Disk/metabolism , Optic Disk/radiation effects , Phenylurea Compounds , Placenta Growth Factor , Platelet-Derived Growth Factor/biosynthesis , Pregnancy Proteins/biosynthesis , Protein Kinase Inhibitors/therapeutic use , Pyridines/therapeutic use , Retina/metabolism , Retina/radiation effects , Retinal Neovascularization/drug therapy , Sorafenib , Vascular Endothelial Growth Factor A/biosynthesisABSTRACT
Both cataract and many vitreoretinal diseases occur more frequently and often at the same time in the elderly population. Therefore, one has to consider whether to combine cataract surgery and vitrectomy or to plan a sequential approach. The aim of the present survey - based on a thorough review of the current literature - is to point out the advantages and disadvantages of a combined versus a sequential approach. Furthermore, practically oriented guidelines have been compiled for finding the right indication for a combined procedure with regard to the underlying vitreoretinal disease.
Subject(s)
Cataract Extraction/methods , Vitrectomy/methods , Aged , Biometry , Combined Modality Therapy , Comorbidity , Humans , Intraoperative Complications/etiology , Intraoperative Complications/prevention & control , Lens Implantation, Intraocular/methods , Lenses, Intraocular , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Prosthesis Design , Reoperation , Risk FactorsABSTRACT
BACKGROUND: The aim of this study was to determine the influence of the lag time between macular detachment and surgical intervention on post-operative visual acuity gain in patients with rhegmatogenous macula-off retinal detachment. PATIENTS AND METHODS: We retrospectively evaluated the medical records of 62 consecutive patients having undergone scleral buckling surgery for rhegmatogenous macula-off retinal detachment. The correlation of gender, age, refraction, number of retinal breaks, development of cataract during follow-up, pre-operative visual acuity and timing of surgical intervention with final visual acuity and post-operative visual acuity gain were determined. Mean follow-up time was 12.7 months. RESULTS: A correlation with final visual acuity was found for pre-operative visual acuity and lag between the beginning of symptoms and surgical intervention. A correlation with visual acuity gain was found only for timing of surgical procedure. When divided into subgroups operated after 0, 1-3, 4-6, or 7-9 days, respectively, visual recovery was better the earlier the patients underwent surgical repair. Compared to surgery at day 0, statistical significance was found only for patients operated 4 or more days after the occurrence of symptoms. CONCLUSION: The first three days seem to represent a relatively safe period during which surgery for macula-off retinal detachment may be postponed without compromising the patient's visual prognosis.
Subject(s)
Macular Degeneration/complications , Macular Degeneration/surgery , Retinal Detachment/complications , Retinal Detachment/surgery , Scleral Buckling , Vision Disorders/diagnosis , Vision Disorders/prevention & control , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Retrospective Studies , Time Factors , Treatment Outcome , Young AdultABSTRACT
An optic disc pit is a rare congenital abnormality of the optic nerve, which in most cases presents as a unilateral finding. Clinically, a greyish oval excavation is seen, most commonly on the temporal side of the optic nerve disc. The optic disc pit alone normally does not lead to substantial symptoms or functional limitations; however, when a maculopathy with intraretinal and/or subretinal fluid and additional other morphological changes in the macula occur, this leads to a decrease in visual acuity. With spectral domain optical coherence tomography (SDOCT) it is possible to identify the various forms of expression, which show different natural courses. Especially the presence of subretinal fluid and defects in the outer retinal layers have a poor prognosis and have the highest risk for further deterioration. Spontaneous resolution can occur but is rare. Observation is recommended in the first step. In cases of progression or pronounced deterioration, surgical intervention is indicated. Many different techniques have been proposed but there is no gold standard at the moment. Most of the surgical approaches comprise pars plana vitrectomy with peeling of the internal limiting membrane (ILM) and gas endotamponade. Newer methods, such as the ILM flap technique also show good results. Generally, it is important to know that postoperative healing and resorption of the fluid often take a long time period of up to 1 year or even longer.
Subject(s)
Eye Abnormalities , Optic Disk , Retinal Diseases , Endotamponade , Humans , Tomography, Optical Coherence , VitrectomyABSTRACT
PURPOSE: Intravitreal injection of the antibody bevacizumab is unofficially becoming more and more the "standard of care" in the treatment of neovascular AMD. After initial concerns about possible systemic adverse events of the drug, intravitreal injection has as yet shown a very good safety profile. Due to the common application of this VEGF inhibitor it is of great importance to report complications that may be related to the use of bevacizumab. In this scope we present a series of patients with predominantly serous detachment of the retinal pigment epithelium (PED), who developed a tear (rip) in the retinal pigment epithelium (RRPE) after intravitreal application of bevacizumab. METHODS: Our data are based on a prospective, consecutive, interventional case series of 420 patients with neovascular AMD. These patients received at least 1 intravitreal application of 1.25 mg bevacizumab within the period of 1 year. Follow-up examinations were every 4-6 weeks. Visits were documented with best corrected visual acuity according to the ETDRS standard, biomicroscopy of the retina, intraocular pressure measurement, evaluation of central retinal thickness, fluorescein angiography and fundus photography. RESULTS: Of 420 patients, 74 were classified as having predominantly serous PED. In the further course 13 out of 74 patients developed RRPE. Patients who had an intact subfoveal RPE, gained vision scores of 1.4+/-8.3 ETDRS letters (span width -15 to 14) despite RRPE or had stable Snellen vision of 0.0+/-0.1 logMar. In contrast patients with no subfoveal RPE due to RRPE showed loss of vision of -6.2+/-7.2 ETDRS letters (span width -15 to 1). CONCLUSION: This case series describes RRPE as a novel complication of intravitreal anti-VEGF therapy with bevacizumab. However, it seems that this complication is limited to the entity of predominantly serous PED. These patients should therefore be informed about the risk of RRPE before initiating anti-VEGF therapy with bevacizumab, although the reverse conclusion to generally exclude patients with PED from anti-VEGF therapy is not justifiable due to therapeutic efficiency and associated gain of vision.
Subject(s)
Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal/adverse effects , Choroidal Neovascularization/drug therapy , Macular Degeneration/drug therapy , Retinal Detachment/chemically induced , Retinal Perforations/chemically induced , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Aged , Aged, 80 and over , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/pharmacology , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Bevacizumab , Female , Humans , Injections , Male , Pigment Epithelium of Eye/drug effects , Prognosis , Prospective Studies , Risk Factors , Time Factors , Visual Acuity , Vitreous BodyABSTRACT
BACKGROUND: Retinal angiomatous proliferation (RAP) is a subform of neovascular age-related macular degeneration (AMD), which is characterized by a particularly poor prognosis. The aim of this study is to describe the loading phase and maintenance phase for RAP during intravitreal anti-VEGF treatment. MATERIAL AND METHODS: A total of 82 eyes in 82 patients with RAP stages 1-3 were treated during upload therapy with repeated intravitreal injections of 1.25 mg bevacizumab at intervals of 4 weeks until the retinal edema resolved. Baseline examination included measurement of the best corrected distance visual acuity (ETDRS chart), central retinal thickness using optical coherence tomography (OCT), and fluorescein angiography (FLA). During maintenance therapy, the patients' distance visual acuity was monitored at 4- to 12-week intervals and OCT or FLA performed if needed. The average follow-up was 7.4 months (SD 4.2). Treatment with intravitreal anti-VEGF therapy was repeated if there was evidence of sub- or intraretinal fluid with a decrease in visual acuity of 5 points or more, increase of the central retinal thickness of 100 microm or more on OCT, or subjective deterioration with verifiable sub- or intraretinal fluid. RESULTS: During upload therapy an improvement in visual acuity of an average of +5.1 letters (mean, n=82 eyes) was observed. During maintenance therapy it was initially possible to sustain this treatment effect. However, 5 months after loading therapy was concluded, a deterioration of -5.5 letters (mean, n=31) was evident in comparison with the end of loading therapy. During the further course deterioration continued (12-month follow-up: -8.6 letters, n=7). Recurrence occurred in 60% of the cases, on average 8 weeks after termination of loading therapy. During an observation period of 6 months (n=66) a total of 3.6 injections were necessary. CONCLUSIONS: Therapy with intravitreal anti-VEGF medications represents a treatment option for RAP, but in the long term the disease continues to progress accompanied by functional deterioration. We thus recommend that patients with RAP be monitored at 4-week intervals to permit early treatment of recurrence.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal/therapeutic use , Macular Degeneration/drug therapy , Retinal Neovascularization/drug therapy , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Aged , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized , Bevacizumab , Data Interpretation, Statistical , Female , Fluorescein Angiography , Follow-Up Studies , Humans , Injections , Macular Degeneration/diagnosis , Male , Papilledema/diagnosis , Papilledema/drug therapy , Retrospective Studies , Time Factors , Tomography, Optical Coherence , Treatment Outcome , Visual Acuity , Vitreous BodyABSTRACT
We compared the ultrastructure of the inner limiting membrane (ILM) and epiretinal tissue in closed and non-closed, idiopathic macular holes (MH). Peeling of ILM and epimacular tissue during vitrectomy was successfully performed on 77 eyes with stage III MH and on 19 eyes with stage IV MH. In 16 additional eyes with non-closed MH, we performed a second vitrectomy with extended ILM removal. The specimens were processed for transmission electron microscopy. Fibrocellular proliferation at the vitreal side of the ILM was found in 57% of MH that were closed by one operation, and in 100% of non-closed MH. Mono- and multilayered cellular membranes as well as native vitreous collagen at the ILM were significantly more frequent in eyes with stage IV MH than in eyes with stage III MH. In non-closed MH, cellular proliferation was mostly seen as irregular cell accumulation, and masses of newly formed collagen were found. Since ILM remnants and collagen represent a stimulus for the early formation of tangential traction preventing successful MH closure, it appears mandatory to create a complete vitreoretinal separation and to remove the ILM and collagen thoroughly during MH surgery.